Shigella sonnei vaccine - GlaxoSmithKline

Drug Profile

Shigella sonnei vaccine - GlaxoSmithKline

Alternative Names: 1790GAHB vaccine; GVGH Shigella sonnei 1790GAHB vaccine

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline
  • Class Bacterial vaccines; Drug conjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Shigella infections

Most Recent Events

  • 31 Aug 2017 GlaxoSmithKline completes a phase I trial in Shigella infections (Prevention, In volunteers) in France (IM) (NCT03089879)
  • 31 Mar 2017 NCT03089879 - added FLS, initiated trial in KDM
  • 16 Mar 2017 GlaxoSmithKline initiates a phase I trial in Shigella infections (Prevention, In volunteers) in France (IM) (NCT03089879)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top